Skip to main content
Journal cover image

Population pharmacokinetics of sildenafil in extremely premature infants.

Publication ,  Journal Article
Gonzalez, D; Laughon, MM; Smith, PB; Ge, S; Ambalavanan, N; Atz, A; Sokol, GM; Hornik, CD; Stewart, D; Mundakel, G; Poindexter, BB; Gaedigk, R ...
Published in: Br J Clin Pharmacol
December 2019

AIMS: To characterize the population pharmacokinetics (PK) of sildenafil and its active metabolite, N-desmethyl sildenafil (DMS), in premature infants. METHODS: We performed a multicentre, open-label trial to characterize the PK of sildenafil in infants ≤28 weeks gestation and < 365 postnatal days (cohort 1) or < 32 weeks gestation and 3-42 postnatal days (cohort 2). In cohort 1, we obtained PK samples from infants receiving sildenafil as ordered per the local standard of care (intravenous [IV] or enteral). In cohort 2, we administered a single IV dose of sildenafil and performed PK sampling. We performed a population PK analysis and dose-exposure simulations using the software NONMEM®. RESULTS: We enrolled 34 infants (cohort 1 n = 25; cohort 2 n = 9) and collected 109 plasma PK samples. Sildenafil was given enterally (0.42-2.09 mg/kg) in 24 infants in cohort 1 and via IV (0.125 or 0.25 mg/kg) in all infants in cohort 2. A 2-compartment PK model for sildenafil and 1-compartment model for DMS, with presystemic conversion of sildenafil to DMS, characterized the data well. Coadministration of fluconazole (n = 4), a CYP3A inhibitor, resulted in an estimated 59% decrease in sildenafil clearance. IV doses of 0.125, 0.5 and 1 mg/kg every 8 hours (in the absence of fluconazole) resulted in steady-state maximum sildenafil concentrations that were generally within the range of those reported to inhibit phosphodiesterase type 5 activity in vitro. CONCLUSIONS: We successfully characterized the PK of sildenafil and DMS in premature infants and applied the model to inform dosing for a follow-up, phase II study.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Br J Clin Pharmacol

DOI

EISSN

1365-2125

Publication Date

December 2019

Volume

85

Issue

12

Start / End Page

2824 / 2837

Location

England

Related Subject Headings

  • Sildenafil Citrate
  • Phosphodiesterase 5 Inhibitors
  • Pharmacology & Pharmacy
  • Models, Biological
  • Injections, Intravenous
  • Infant, Premature, Diseases
  • Infant, Premature
  • Infant, Newborn
  • Infant
  • Hypertension, Pulmonary
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gonzalez, D., Laughon, M. M., Smith, P. B., Ge, S., Ambalavanan, N., Atz, A., … Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee, . (2019). Population pharmacokinetics of sildenafil in extremely premature infants. Br J Clin Pharmacol, 85(12), 2824–2837. https://doi.org/10.1111/bcp.14111
Gonzalez, Daniel, Matthew M. Laughon, P Brian Smith, Shufan Ge, Namasivayam Ambalavanan, Andrew Atz, Gregory M. Sokol, et al. “Population pharmacokinetics of sildenafil in extremely premature infants.Br J Clin Pharmacol 85, no. 12 (December 2019): 2824–37. https://doi.org/10.1111/bcp.14111.
Gonzalez D, Laughon MM, Smith PB, Ge S, Ambalavanan N, Atz A, et al. Population pharmacokinetics of sildenafil in extremely premature infants. Br J Clin Pharmacol. 2019 Dec;85(12):2824–37.
Gonzalez, Daniel, et al. “Population pharmacokinetics of sildenafil in extremely premature infants.Br J Clin Pharmacol, vol. 85, no. 12, Dec. 2019, pp. 2824–37. Pubmed, doi:10.1111/bcp.14111.
Gonzalez D, Laughon MM, Smith PB, Ge S, Ambalavanan N, Atz A, Sokol GM, Hornik CD, Stewart D, Mundakel G, Poindexter BB, Gaedigk R, Mills M, Cohen-Wolkowiez M, Martz K, Hornik CP, Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee. Population pharmacokinetics of sildenafil in extremely premature infants. Br J Clin Pharmacol. 2019 Dec;85(12):2824–2837.
Journal cover image

Published In

Br J Clin Pharmacol

DOI

EISSN

1365-2125

Publication Date

December 2019

Volume

85

Issue

12

Start / End Page

2824 / 2837

Location

England

Related Subject Headings

  • Sildenafil Citrate
  • Phosphodiesterase 5 Inhibitors
  • Pharmacology & Pharmacy
  • Models, Biological
  • Injections, Intravenous
  • Infant, Premature, Diseases
  • Infant, Premature
  • Infant, Newborn
  • Infant
  • Hypertension, Pulmonary